The following questions and topics will be covered in this presentation.
- Buprenorphine’s analgesia can best be described as:
A. Partial agonist
B. Agonist antagonist
C. Potent agonist with multi-receptor action
D. Buprenorphine is analgesic but only for mild to moderate pain
- Buprenorphine’s safety profile can best be described as
A. Similar to other opioids
B. Significant safer than other opioids
C. Risk free opioid
D. Riskier than other opioids
- The naloxone in buprenorphine if used sublingually is:
A. Present to block other opioids if ingested
B. An abuse deterrent only
C. Is active only if buprenorphine is used intranasally or injected
D. 2 and 3
- Buprenorphine’s effect of QT prolongation on EKG
A. Presents a significant risk
B. Presents a moderate risk but greater than that of oxycodone
C. Is not a significant risk in patients without other risk factors
D. Presents no risk of QT prolongation
- Buprenorphine’s ceiling effect for respiratory depression
A. Has been demonstrated in mice but not humans
B. Has been demonstrated in adults but not young children
C. Means there is no respiratory depression from using buprenorphine
D. Means you cannot overdose on buprenorphine.
